Intuitive Surgical, Inc. (ISRG), the maker of the da Vinci robotic surgical system, closed its most recent session near $393 after a challenging stretch that saw the shares slide roughly 30% from their early-2026 peak. The stock touched a 52-week high of about $604 in January before falling to a 52-week low near $328 in late July, and it has since recovered only part of that decline.
Against that backdrop, $500 has become a widely discussed price target. It represents a clean psychological milestone, sits roughly 27% above recent levels, and is backed by explicit targets from several sell-side analysts. Because the level is meaningfully higher than the current price but still below the prior all-time high, it is a realistic, measurable objective rather than a stretch goal.
Intuitive Surgical is the dominant player in robot-assisted minimally invasive surgery, with more than 10,000 da Vinci systems installed worldwide and a rapidly growing Ion endoluminal platform used for lung biopsies. The business model is built around recurring revenue: hospitals purchase the systems, then continue buying instruments and accessories for every procedure. This razor-and-blade dynamic has helped the company grow revenue at a double-digit pace through market cycles.
The most recent quarterly results showed the underlying business remains strong. Revenue rose roughly 18% year over year, driven by about 15% growth in worldwide da Vinci procedures and a roughly 36% jump in Ion procedures. Adjusted earnings per share (EPS) grew nearly 28%. Yet the shares fell sharply after the report, as investors focused on a slowdown in U.S. procedure growth tied to insurance subsidy changes, deferred procedures, and softer bariatric surgery volumes.
Several factors support a potential move back to $500. First, the launch of the da Vinci 5 system, with integrated force feedback and AI-driven case insights, is expected to drive system placements and higher utilization. Analysts at firms including Goldman Sachs and BTIG have pointed to da Vinci 5 as a key contributor to revenue growth in the coming years.
Second, competition appears less threatening in the near term than feared. Oppenheimer's upgrade cited workflow challenges for Johnson & Johnson's (JNJ) Ottava system and footprint constraints for Medtronic's (MDT) Hugo platform, suggesting the da Vinci franchise faces no immediate credible U.S. challenger. Management also reaffirmed full-year worldwide da Vinci procedure growth guidance of roughly 13.5% to 15.5%, signaling confidence that the domestic slowdown is temporary.
Third, the valuation, while still premium, has compressed. The stock trades at a forward price-to-earnings (P/E) ratio in the mid-30s after spending much of the prior year well above 40 times, giving the shares room to re-rate if procedure growth stabilizes.
The biggest risk is that the U.S. procedure slowdown proves more persistent than bulls expect. If deferred elective surgeries and bariatric softness continue, the revenue growth that justifies a premium multiple could disappoint. Competition also remains a longer-term overhang, particularly from J&J's FDA-cleared Ottava system and lower-priced Chinese rivals in international markets.
Valuation is another obstacle. Even after the pullback, Intuitive Surgical trades at a substantial premium to the broader medical device sector. A further shift in investor sentiment, driven by policy changes affecting the Affordable Care Act or Medicare reimbursement, could keep the multiple compressed. Deutsche Bank, one of the more cautious voices, carries a price target near $366, below the current price.
Wall Street remains broadly constructive. The consensus rating is a Strong Buy, with the average 12-month price target in the mid-to-high $400s and the highest targets reaching toward the $600s. Notably, Oppenheimer, Citi, and UBS each hold $500 targets, lending credibility to that specific level. However, the range of targets is unusually wide, from below $400 to well above $600, reflecting genuine disagreement about how quickly U.S. growth can reaccelerate.
From a technical analysis perspective, $500 functions as a psychological resistance level that also aligns with a cluster of analyst targets, potentially making it a meaningful supply zone if the shares approach it. The 52-week low near $328 is the critical support level, while the prior high near $604 represents the ultimate recovery target. The recent stabilization in the high $300s to low $400s suggests the stock is attempting to build a base after its sharp decline, but a durable move toward $500 would likely require sustained momentum above the low-to-mid $400s.
For investors tracking whether Intuitive Surgical can regain its footing, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to monitor changing conditions. The platform uses artificial intelligence to continuously analyze thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. Traders can use these signals to surface new opportunities, keep tabs on existing positions, and identify shifting market trends more efficiently. Explore the AI Daily Buy/Sell Signals to see how automated analysis can support your own research process.
Reaching $500 is a realistic but not guaranteed outcome for Intuitive Surgical. The company's durable growth engine, dominant market position, and a cluster of matching analyst targets all support the case, and the level sits well below the prior high. The primary obstacle is execution: the stock likely needs a clear stabilization and reacceleration in U.S. procedure volumes, along with sustained confidence in the da Vinci 5 rollout, before investors are willing to pay a higher multiple again. Investors should monitor procedure growth trends, system placements, and competitive developments, while watching whether the shares can hold support above the recent lows as the recovery progresses.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | +2.12% | ||
| BSX - ISRG | 73% Closely correlated | +0.88% | ||
| SYK - ISRG | 64% Loosely correlated | -0.34% | ||
| NTRA - ISRG | 54% Loosely correlated | +0.34% | ||
| GKOS - ISRG | 51% Loosely correlated | -1.39% | ||
| PODD - ISRG | 49% Loosely correlated | -0.05% | ||
More | ||||
| Ticker / NAME | Correlation To ISRG | 1D Price Change % |
|---|---|---|
| ISRG | 100% | +2.12% |
| ISRG (2 stocks) | 99% Closely correlated | +0.92% |
| Pharmaceuticals: Other (50 stocks) | 61% Loosely correlated | +0.89% |
| Pharmaceuticals (154 stocks) | 2% Poorly correlated | +1.17% |